Tech Company Financing Transactions
InventisBio Funding Round
On 6/1/2017, InventisBio received $19 million in Series B funding from OrbiMed and Lilly Asia Ventures.
Transaction Overview
Company Name
Announced On
6/1/2017
Transaction Type
Venture Equity
Amount
$19,000,000
Round
Series B
Investors
OrbiMed (Lead Investor) (Jonathan Wang)
Proceeds Purpose
This new investment will accelerate our product development through phase 1 clinical trials, said Dr Wang, InventisBio co-founder, chair and CEO.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1000 Zhangheng Rd. Building 63 Pudong New District
Shanghai, 201203
China
Shanghai, 201203
China
Phone
Website
Email Address
Overview
InventisBio is a dynamic and fast-growing global biotech company with multiple therapeutic agents at clinical stage. InventisBio focuses on discovery and development of novel therapeutics in the areas of oncology and metabolic diseases to address unmet medical needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Yaolin Wang
Chief Medical Officer
Ling Zhang
VP - R & D
David Dai
VP - R & D
Jack Jiang
Browse more venture capital transactions:
Prev: 6/1/2017: Hyalex Orthopaedics venture capital transaction
Next: 6/1/2017: Outcome Health venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs